From: Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies
Sample ID | MGMT promoter methylation (PMR) | EGFR amplification | Tumor volume >0.2 cm3 at day |
---|---|---|---|
HROG05 | |||
Tumor | M (34,5) | 82× | – |
PDX P2 | U (0) | 12× | 60 |
HROG06 | |||
Tumor | U (0) | 82× | – |
PDX P0 | U (0) | 75× | 54 |
PDX P1 | U (0) | 69× | 24 |
PDX P2 | U (0) | 103× | 40 |
PDX P3 | U (0) | 123× | 27 |
PDX P4 | U (0) | 144× | 25 |
PDX P5 | U (0) | 147× | 19 |
HROG07 | |||
Tumor | U (0) | 12× | – |
PDX P2 | U (0) | 152× | 82 |
PDX P4 | U (0) | 96× | 98 |
HROG12 | |||
Tumor | U (1,4) | 37× | – |
PDX P0 | U (0) | 52× | 123 |
HROG13 | |||
Tumor | U (3,9) | 1× | – |
PDX P1 | M (4) | 2× | 25 |
PDX P2 | M (5) | 2× | 31 |
PDX P3 | M (15) | 2× | 46 |
HROG17 | |||
Tumor | M (14) | 4× | – |
PDX P2 | M (11) | 1× | 59 |
HROG22 | |||
Tumor | M (22,2) | 1× | – |
PDX P0 | M (6) | 2× | 158 |
PDX P1 | M (22) | 2× | 54 |
PDX P3 | M (73) | 1× | 46 |
PDX P5 | M (97) | 2× | 26 |
HROG33 | |||
Tumor | U (0) | 31× | – |
PDX P1 | U (0) | 67× | 90 |
HROG59 | |||
Tumor | U (0) | 16× | – |
PDX P2 | U (0) | 85× | 68 |
PDX P3 | U (0) | 92× | 31 |
PDX P4 | U (0) | 47× | 31 |
PDX P5 | U (0) | 36× | 54 |